On the evening of October 29, YAHONG PHARMACEUTICAL (688176.SH) disclosed its third quarter report. The company achieved revenue of 58.4582 million yuan in the third quarter, a year-on-year increase of 1903.16%; for the first three quarters, the cumulative revenue was 0.139 billion yuan, a year-on-year increase of 4537.79%. The revenue growth is mainly attributed to the company starting to sell its drug Pipatinib Tablets (brand name: Dipatte) and Nilotinib Maleate Tablets (brand name: Ouyoubi) in the fourth quarter of 2023. Commercial promotion has steadily progressed during this reporting period, leading to an increase in sales volume.
亚虹医药今年前三季度累计营收1.39亿元 两款商业化产品持续放量
Yahong Pharmaceuticals accumulated revenue of 0.139 billion yuan in the first three quarters of this year, with two commercialized products continuing to ramp up production.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated